Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 11/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 11/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 11/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 6/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8807072 | 0.74 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CNISCHMAOA | |
| SCHEMBL112179 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL4060690 | 0.72 | — | — | |
| SCHEMBL28353595 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL1690425 | 0.72 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CNISCHMAOA | |
| Hydrochloric Acid SCHEMBL6689660 | 0.72 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CNISCHMAOA | |
| Water SCHEMBL27801507 | 0.72 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CNISCHMAOA | |
| SCHEMBL9439738 | 0.70 | — | — | |
| SCHEMBL12945682 | 0.70 | — | — | |
| SCHEMBL7402699 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745365-B2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3312292-B1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORP (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-1885875-B1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORP (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190031629-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2019-01-31 | — | — | US | disclosed |
| US-10077244-B2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3312292-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | Promega Corporation (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2778234-B1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORP (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2545041-B1 | BIOLUMINESCENT ASSAYS USING CYANOBENZOTHIAZOLE COMPOUNDS | PROMEGA CORP (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20160176830-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-06-23 | — | — | US | disclosed |
| EP-2331517-B1 | BIOLUMINESCENT ASSAYS USING CYANOBENZOTHIAZOLE COMPOUNDS | PROMEGA CORP (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20100075351-A1 | BIOLUMINESCENT DETECTION OF CYANOHYDROXY BENZOTHIAZOLE COMPOUNDS | PROMEGA CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010030343-A1 | BIOLUMINESCENT ASSAYS USING CYANOBENZOTHIAZOLE COMPOUNDS | PROMEGA CORPORATION (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-2142665-A2 | LUMINESCENT LIVE AND DEAD CELL ASSAY | PROMEGA CORPORATION (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008127677-A9 | LUMINESCENT LIVE AND DEAD CELL ASSAY | PROMEGA CORP (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20080299593-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008127677-A2 | LUMINESCENT LIVE AND DEAD CELL ASSAY | PROMEGA CORPORATION (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1935986-A2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1885875-A2 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORPORATION (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070015790-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2007-01-18 | — | — | US | disclosed |
| WO-2006130551-A2 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745365-B2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | ADRA2A 4171/4885ADRA2B 3453/4885ADRA2C 3771/4885 |
| US-10077244-B2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | ADRA2A 4140/4885ADRA2B 3403/4885ADRA2C 3678/4885 |
| US-20080299593-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | ADRA2A 4171/4885ADRA2B 3453/4885ADRA2C 3771/4885 |
| US-20100075351-A1 | BIOLUMINESCENT DETECTION OF CYANOHYDROXY BENZOTHIAZOLE COMPOUNDS | BLVRB, BTD, BBOX1 | ADRA2A 4072/4885ADRA2B 3188/4885ADRA2C 3848/4885 |
| US-20190031629-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | GLB1, NOD1, PYCARD | ADRA2A 4171/4885ADRA2B 3453/4885ADRA2C 3771/4885 |
| US-20160176830-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | GLB1, NOD1, PYCARD | ADRA2A 4140/4885ADRA2B 3403/4885ADRA2C 3678/4885 |
| US-20070015790-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | ADRA2A 4229/4885ADRA2B 3506/4885ADRA2C 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.